NG2 antigen is a therapeutic target in human acute leukemia
Institute Josep Carreras
Filing date: 4 Aug, 2018
P14748PCT00
ICREA selecciona a los investigadores únicamente en base a sus logros científicos. No obstante, la excelencia científica desemboca a menudo en la invención de nuevas tecnologías y soluciones increíbles. Cuando eso sucede, ICREA apoya plenamente el aprovechamiento de estas oportunidades.
Los catedráticos de investigación de ICREA trabajan en varias universidades y centros de investigación. De ahí que la titularidad de cualquier propiedad industrial se comparta siempre entre ICREA y la institución de acogida. Para que las negociaciones sean lo más ágiles y concluyentes posible, si surge la oportunidad, las instituciones de acogida pueden estudiar y emprender actividades de transferencia de tecnología en nombre de ICREA. ICREA apoya las acciones encaminadas a tal aprovechamiento y presta su asesoramiento durante todo el proceso.
Consulte nuestras tecnologías actuales y contacte con ICREA para saber más.
-
Life & Medical Sciences
NG2 antigen is a therapeutic target in human acute leukemia
Institute Josep Carreras
CLOSE -
Life & Medical Sciences
METHODS FOR IMPROVING RESPONSE TO ANTI-LIF ANTIBODY TREATMENT IN INDIVIDUALS WITH CANCER
CLOSE METHODS FOR IMPROVING RESPONSE TO ANTI-LIF ANTIBODY TREATMENT IN INDIVIDUALS WITH CANCER
Filing date: 18 Jun, 2018
-
Life & Medical Sciences
METHODS OF QUANTIFYING LIF AND USES THEREOF
CLOSE METHODS OF QUANTIFYING LIF AND USES THEREOF
Filing date: 18 Jun, 2018
-
Life & Medical Sciences
COMBINATION OF LIF INHIBITORS AND PLATINUM-BASED ANTINEOPLASTIC AGENTS FOR USE IN TREATING CANCER
CLOSE COMBINATION OF LIF INHIBITORS AND PLATINUM-BASED ANTINEOPLASTIC AGENTS FOR USE IN TREATING CANCER
Filing date: 18 Jun, 2018
-
Life & Medical Sciences
LIF DOSAGES
CLOSE LIF DOSAGES
Filing date: 14 May, 2018
-
Life & Medical Sciences
COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN TREATING CANCER
Mosaic Biomedicals, S.L.U., et al
CLOSE COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN TREATING CANCER
Mosaic Biomedicals, S.L.U., et al
Filing date: 12 Apr, 2018
18382248.5-1111
-
Experimental Sciences & Mathematics
Photocatalyst system and use thereof in a photocatalytic process
CLOSE Photocatalyst system and use thereof in a photocatalytic process
Filing date: 15 Nov, 2017
EP17382772
-
Engineering Sciences
ID0097-00 / Confidential
ICFO and ICREA
CLOSE ID0097-00 / Confidential
ICFO and ICREA
Filing date: 6 Nov, 2017
Licenced date: 24 Nov, 2017
PCT/ES2017/070734
-
Experimental Sciences & Mathematics
LAYERED ELECTROOSMOTIC STRUCTURE
Osmotex AG
CLOSE LAYERED ELECTROOSMOTIC STRUCTURE
A layered structure for pumping fluid by electroosmotic transport is provided. The layered structure comprising: a first layer, wherein the first layer is made from an ion perm selective material having openings therein that permit the fluid to flow therethrough, and wherein the openings in the first layer that permit the fluid to flow therethrough create a porosity of less than 10%; and a second layer, wherein the second layer is an electroosmotic layer. The layered structure having a net fluid flow direction that extends through the first layer and the second layer, wherein the layered structure has a region that permits fluid to flow in a direction that is non- parallel to a net fluid flow direction, and wherein the region is located between the first layer and the surface of the second layer that is furthest from the first layer. An electroosmodialysis apparatus may also be provided that comprises two layered structures.
Osmotex AG
Filing date: 8 Sep, 2017
WO/2018/046659
-
Life & Medical Sciences
Protein expression assays and methods
CRG
CLOSE Protein expression assays and methods
CRG
Filing date: 31 May, 2017
1708679.4
